Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B: The Subgroup (N=33) With No Neutralizing Anti-AAV Antibodies (NAb-Negative):
- 100% expressed endogenous FIX at therapeutic levels (mean 39.0 IU/dL)
- 100% remained prophylaxis-free over 4 years—zero returned to prophylaxis
- Exogenous FIX consumption decreased by 99%
- 85% reduction in bleeds (all, spontaneous, joint)
- Safety: Treatment-related AEs only first 3 months; transient ALT elevations 18%, all manageable
This enables direct comparison to other haemophilia B gene therapies where only NAb-negative patients were enrolled.
HOPE-B’s Inclusive Design
HOPE-B is the first—and currently only—haemophilia B gene therapy trial to include patients with pre-existing AAV neutralizing antibodies for treatment with etranacogene dezaparvovec.
Very recently, the NEJM paper presented 5-year data of the full cohort (NAb-negative and NAb-positive; N=54).
Congratulations to Priyanka Raheja and co-authors!”
Read the full article here.
Article: Etranacogene dezaparvovec in participants with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: A 4-year subgroup analysis (HOPE-B)
Authors: Priyanka Raheja, Niamh O’Connell, Peter Verhamme, Peter Kampmann, Richard S. Lemons, Fei Wang, Sean Gill, Paul E. Monahan, Sandra Le Quellec, Frank W. G. Leebeek
Stay updated on all scientific advances with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies